NCT06433557View on ClinicalTrials.gov

A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With Achondroplasia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 26, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2027

Conditions
Achondroplasia
Interventions
DRUG

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

For navepegritide, a once weekly s.c. dose of 100 μg CNP/kg. For lonapegsomatropin, a once weekly s.c. dose of lonapegsomatropin 0.30 mg hGH/kg as starting dose. Treatment duration of up to 156 weeks.

Trial Locations (3)

2100

Ascendis Pharma Investigational Site, Copenhagen

D01 YC76

Ascendis Pharma Investigational Site, Dublin

W1W 5AH

Ascendis Pharma Investigational Site, London

All Listed Sponsors
lead

Ascendis Pharma Growth Disorders A/S

INDUSTRY